聚二氧环己酮合成补片在两阶段乳房再造中的短期结局:单中心对比研究
单中心回顾性队列分析524例患者919个组织扩张器,比较聚二氧环己酮(PDO)补片、生物补片与无补片组的早期并发症。
要点
- PDO补片组感染率10.6%,生物补片组6.6%,无补片组6.2%,差异无统计学意义。
- 补片类型并非感染独立危险因素,皮瓣质量与患者因素影响可能更大。
核心结论
- PDO补片、生物补片或无补片行组织扩张器置入的短期结局相当。
- 补片类型与感染及取出无独立关联,同侧放疗是感染唯一显著相关因素。
研究设计与样本
- 单中心回顾性队列研究,纳入2021至2024年乳腺癌切除后即刻组织扩张器置入患者。
- 共分析524例患者919个组织扩张器,按补片类型分组行单因素及多因素回归分析。
主要发现
- PDO补片组占27.7%,生物补片组占52.9%,无补片组占19.5%。
- 组织扩张器感染发生于70个乳房(7.6%)、55例患者(10.5%)。
- PDO补片组感染率10.6%,生物补片组6.6%,无补片组6.2%(P=NS)。
- 取出扩张器发生于120个乳房(13.0%),补片类型间无差异。
关键数值与推荐
- PDO补片组感染率10.6%,生物补片组6.6%,无补片组6.2%(P=NS)。
- 取出扩张器发生率13.0%,补片类型间无差异。
临床怎么用
- PDO补片可作为生物补片的低成本替代用于两阶段乳房再造软组织支持。
- 术前应重点评估同侧放疗史及皮瓣质量,而非仅依据补片类型预判感染风险。
局限性
- 单中心回顾性研究,证据等级为3级(治疗性)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Polydioxanone (PDO) mesh offers a more cost-effective option than biologic mesh for soft tissue support for 2-stage breast reconstruction with tissue expansion but differences in complication rates have not been well established. OBJECTIVES: The purpose of this study was to present the early postoperative complications recorded by a single center following immediate tissue expander (TE) insertion for breast reconstruction using PDO mesh, biologic mesh, or no mesh. METHODS: A retrospective cohort study was performed of patients undergoing immediate TE insertion following mastectomy over a 3-year period (2021-2024) at a single academic center. Patients were grouped by mesh type. Univariate and multivariate regression analyses were performed. RESULTS: A total of 919 TEs in 524 patients were analyzed: 27.7% with PDO mesh, 52.9% with biologic mesh, and 19.5% with no mesh. TE infection occurred in 70 breasts (7.6%) in 55 patients (10.5%), with infection rates of 10.6% in the PDO mesh group, 6.6% in the biologic mesh group, and 6.2% in the no mesh group (P = NS). Ipsilateral radiation exposure was the only factor significantly associated with infection (odds ratio, 7.2; P = .008). Prepectoral reconstructions resulted in higher infection rates than subpectoral cases, but mesh type was not independently associated with infection. Explantation occurred in 120 breasts (13.0%) with no difference between mesh types. CONCLUSIONS: Short-term outcomes following TE placement were comparable among patients receiving PDO mesh, biologic mesh, or no mesh. These findings suggest that mastectomy flap quality and patient factors may have a greater impact on complications than mesh type, especially with prepectoral placement. LEVEL OF EVIDENCE: 3 (THERAPEUTIC): For image description, please refer to the figure legend and surrounding text.
引用
- Abbott EN, Li R, King D, et al. Short-term Outcomes of Polydioxanone Synthetic Mesh in 2-stage Breast Reconstruction: A Single-Center Comparative Study. Aesthet Surg J. 2026. PMID: 41578861. doi:10.1093/asj/sjag019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。